RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
RELIEF THERAPEUTICS Holding Stock

RELIEF THERAPEUTICS Holding Stocks 2024

RELIEF THERAPEUTICS Holding Stocks

11.75 M

Ticker

RLF.SW

ISIN

CH0100191136

WKN

A1H80W

In 2024, RELIEF THERAPEUTICS Holding had 11.75 M outstanding stocks, a 0% change from the 11.75 M stocks in the previous year.

The RELIEF THERAPEUTICS Holding Stocks history

YEARNUMBER OF STOCKS (undefined CHF)
2028e0.01
2027e0.01
2026e0.01
2025e0.01
2024e0.01
20230.01
20220.01
20210.01
20200.01
20192.1
20182.05
20171.99
20161.27
20150.59
20140.48
20130.17
20120.07
20110.07
20100.07
20090.07
20080.13
20070.1
20060.04

RELIEF THERAPEUTICS Holding shares outstanding

The number of shares was RELIEF THERAPEUTICS Holding in 2023 — This indicates how many shares 11.752 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue RELIEF THERAPEUTICS Holding earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates RELIEF THERAPEUTICS Holding's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of RELIEF THERAPEUTICS Holding’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating RELIEF THERAPEUTICS Holding's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

RELIEF THERAPEUTICS Holding Aktienanalyse

What does RELIEF THERAPEUTICS Holding do?

RELIEF THERAPEUTICS Holding SA is a Swiss biotech company that specializes in the research and development of novel therapies for the treatment of serious diseases. The company was founded in 2016 and is based in Geneva. The history of RELIEF THERAPEUTICS began with the discovery of a promising molecule called Aviptadil. Aviptadil is a synthetic peptide derived from the natural hormone VIP (Vasoactive Intestinal Peptide). It has the ability to regulate a variety of biological processes in the body and has shown promise as a therapy for a range of diseases. Since its inception, the company has formed a number of partnerships and collaborations with other companies and research institutions to support its research projects and bring its technology to market. The business model of RELIEF THERAPEUTICS is based on the research and development of innovative therapies for a variety of serious diseases for which there is currently no effective treatment. The company focuses on the research and development of peptides and proteins as a new class of therapeutic agents. RELIEF THERAPEUTICS has several business segments active in drug development. The first segment is the respiratory diseases segment, in which the company utilizes its core expertise in the development of Aviptadil to explore innovative therapies for severe respiratory diseases such as idiopathic pulmonary fibrosis (IPF), acute and chronic respiratory distress syndromes (ARDS/CRDS), and asthma. Another important segment of RELIEF THERAPEUTICS is cancer research. The company is working on the development of new cancer therapies based on Aviptadil, targeting the regulation of tumor growth and metastasis formation. The third segment of the company is pain therapy. Here, RELIEF THERAPEUTICS is working on the development of peptide-based analgesics to alleviate pain in various conditions such as cancer, neuropathic pain, and postoperative pain. RELIEF THERAPEUTICS currently offers several products based on Aviptadil. One of these products is RLF-100, also known as ZYESAMI, a potential drug for the treatment of severe respiratory diseases such as ARDS/CRDS and COVID-19. RLF-100 is an inhalable Aviptadil specifically developed for the treatment of respiratory diseases and has shown high efficacy in clinical studies. Another product from RELIEF THERAPEUTICS is RLF-888, a potential drug for the treatment of neuropathic pain. RLF-888 has been developed as a peptide-based analgesic and has shown promising results in preclinical studies. In 2021, RELIEF THERAPEUTICS acquired a majority stake in APR Applied Pharma Research SA, expanding its product range and business areas. APR is increasingly gaining importance in the acute aplastic pain market and could prove to be an important part of RELIEF THERAPEUTICS' product diversity in the future. Overall, RELIEF THERAPEUTICS has positioned itself as a promising player in the biotech industry and continues to strive to develop innovative therapies for serious diseases to help patients worldwide. RELIEF THERAPEUTICS Holding ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating RELIEF THERAPEUTICS Holding's Shares Outstanding

RELIEF THERAPEUTICS Holding's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in RELIEF THERAPEUTICS Holding’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding RELIEF THERAPEUTICS Holding’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in RELIEF THERAPEUTICS Holding’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about RELIEF THERAPEUTICS Holding stock

How many stocks are there of RELIEF THERAPEUTICS Holding?

The current number of stocks of RELIEF THERAPEUTICS Holding is 11.75 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of RELIEF THERAPEUTICS Holding are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of RELIEF THERAPEUTICS Holding evolved in recent years?

The number of shares of RELIEF THERAPEUTICS Holding has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. RELIEF THERAPEUTICS Holding as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of RELIEF THERAPEUTICS Holding?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does RELIEF THERAPEUTICS Holding pay?

Over the past 12 months, RELIEF THERAPEUTICS Holding paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, RELIEF THERAPEUTICS Holding is expected to pay a dividend of 0 CHF.

What is the dividend yield of RELIEF THERAPEUTICS Holding?

The current dividend yield of RELIEF THERAPEUTICS Holding is .

When does RELIEF THERAPEUTICS Holding pay dividends?

RELIEF THERAPEUTICS Holding pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of RELIEF THERAPEUTICS Holding?

RELIEF THERAPEUTICS Holding paid dividends every year for the past 0 years.

What is the dividend of RELIEF THERAPEUTICS Holding?

For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.

In which sector is RELIEF THERAPEUTICS Holding located?

RELIEF THERAPEUTICS Holding is assigned to the 'Health' sector.

Wann musste ich die Aktien von RELIEF THERAPEUTICS Holding kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of RELIEF THERAPEUTICS Holding from 9/26/2024 amounting to 0 CHF, you needed to have the stock in your portfolio before the ex-date on 9/26/2024.

When did RELIEF THERAPEUTICS Holding pay the last dividend?

The last dividend was paid out on 9/26/2024.

What was the dividend of RELIEF THERAPEUTICS Holding in the year 2023?

In the year 2023, RELIEF THERAPEUTICS Holding distributed 0 CHF as dividends.

In which currency does RELIEF THERAPEUTICS Holding pay out the dividend?

The dividends of RELIEF THERAPEUTICS Holding are distributed in CHF.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von RELIEF THERAPEUTICS Holding

Our stock analysis for RELIEF THERAPEUTICS Holding Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of RELIEF THERAPEUTICS Holding Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.